OneDigital Investment Advisors LLC Makes New Investment in DexCom, Inc. $DXCM

Posted by Brenda Bartman on Aug 17th, 2026

OneDigital Investment Advisors LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the second quarter, HoldingsChannel reports. The institutional investor acquired 171,242 shares of the medical device company’s stock, valued at approximately $11,533,000.

Other large investors also recently modified their holdings of the company. BOKF NA increased its holdings in DexCom by 175.7% during the 4th quarter. BOKF NA now owns 35,314 shares of the medical device company’s stock worth $2,344,000 after purchasing an additional 22,505 shares during the last quarter. Stephens Investment Management Group LLC boosted its stake in shares of DexCom by 21.1% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,042,801 shares of the medical device company’s stock valued at $69,211,000 after buying an additional 181,701 shares during the last quarter. Eurizon Capital SGR S.p.A. purchased a new position in shares of DexCom during the 4th quarter valued at approximately $3,231,000. Goodman Advisory Group LLC acquired a new stake in shares of DexCom during the fourth quarter worth approximately $1,293,000. Finally, Employees Retirement System of Texas bought a new stake in shares of DexCom in the fourth quarter worth $37,871,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on DXCM shares. BTIG Research reaffirmed a “buy” rating and issued a $90.00 price target (up from $80.00) on shares of DexCom in a report on Friday, July 31st. Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. TD Cowen reissued a “buy” rating on shares of DexCom in a research report on Friday, July 31st. Bank of America reduced their price target on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Finally, Stifel Nicolaus set a $95.00 price objective on DexCom and gave the company a “buy” rating in a report on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $88.71.

Get Our Latest Analysis on DXCM

DexCom Stock Performance

DexCom stock opened at $89.75 on Monday. The firm’s 50-day moving average is $76.08 and its 200-day moving average is $70.34. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $91.96. The company has a market cap of $33.87 billion, a P/E ratio of 35.47, a PEG ratio of 1.51 and a beta of 1.41.

DexCom (NASDAQ:DXCM – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. During the same period in the previous year, the business posted $0.48 EPS. The company’s quarterly revenue was up 13.1% on a year-over-year basis. On average, equities analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the transaction, the executive vice president directly owned 106,353 shares in the company, valued at $8,034,969.15. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,912 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $73.00, for a total value of $358,576.00. Following the transaction, the executive vice president directly owned 100,361 shares of the company’s stock, valued at $7,326,353. This trade represents a 4.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 99,794 shares of company stock worth $7,373,321. Insiders own 0.28% of the company’s stock.

DexCom Company Profile

(Free Report)

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.